BioSenic SA Logo

BioSenic SA

Develops therapies for autoimmune diseases, inflammation, and bone disorders.

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT

Description

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 17:20
BioS - 2nd EGM - Signed deed(1525437.1).pdf
French 2.4 MB
2025-11-12 10:00
BioSenic SA_Proxy EGM_FR_OC draft 2025 11 07(1518280.1).pdf
French 322.9 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
BioSenic SA_Convening notice_2025_FR_2025 11 04(1506176.1).pdf
French 302.6 KB
2025-11-12 10:00
BioSenic SA_ Information on shareholders' rights EGM_FR_2025 11 07(1506226.1).p…
French 152.9 KB
2025-11-12 10:00
BIOS_PR_GMs-2025_FR_2025 11 07(1506246.1).pdf
French 214.9 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-10-28 07:00
BIOS_H1-PR Report_FR_2025 10 28_final.pdf
French 371.5 KB
2025-09-29 22:00
BioSenic SA_ Information on shareholders' rights GMs_FR_2025 09 29.pdf
French 160.6 KB
2025-09-29 22:00
BioSenic - (FR) Warrant_Plan - 2025 09 29.pdf
French 316.3 KB
2025-09-29 22:00
BioSenic - Rapport de gestion - 20250929-final.pdf
French 616.8 KB
2025-09-29 22:00
BioSenic SA-rapport du commissaire-31 12 2024_signed.pdf
French 1.6 MB
2025-09-29 22:00
BioSenic___Rapport_spécial_CA_(Art_7_228_CSA)_2025_09_29.docx.pdf
French 348.2 KB
2025-09-29 22:00
20250817_Rapport annuel 2024_FR_Final.pdf
French 2.0 MB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioSenic SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-16 Rieger Francois Board Sell 2,500,000 25,000.00 EUR
2024-08-06 Rieger Francois Board Sell 868,653 7,186.87 EUR
2024-08-05 POMI SCHNEITER VERONIQUE Board Sell 534,750 4,331.47 EUR
2024-08-02 POMI SCHNEITER VERONIQUE Board Sell 193,900 1,609.37 EUR
2024-08-01 Rieger Francois Board Sell 1,236,684 11,463.87 EUR
2024-08-01 POMI SCHNEITER VERONIQUE Board Sell 140,003 1,246.03 EUR
2024-07-31 POMI SCHNEITER VERONIQUE Board Sell 503,771 4,685.07 EUR
2024-07-30 POMI SCHNEITER VERONIQUE Board Sell 360,021 3,348.20 EUR
2024-07-29 POMI SCHNEITER VERONIQUE Board Sell 372,893 3,430.62 EUR
2024-07-24 POMI SCHNEITER VERONIQUE Board Sell 2,168,361 21,033.10 EUR

Peer Companies

Nicox S.A. Logo
Ophthalmology company developing therapies based on a nitric oxide-donating platform.
France
COX
NLS Pharmaceutics Ltd. Logo
Clinical-stage biopharma firm developing therapies for rare and complex CNS disorders.
United States of America
NLSP
NovoCure Ltd Logo
Develops a non-invasive cancer therapy using electric fields to disrupt solid tumors.
United States of America
NVCR
NUFORMIX PLC Logo
Pharmaceutical developer using cocrystal technology to repurpose drugs for fibrosis.
United Kingdom
NFX
Nurix Therapeutics, Inc. Logo
Clinical-stage biopharma developing protein degradation therapies for various diseases.
United States of America
NRIX
OLIPASS CORPORATION Logo
An R&D company developing RNA therapeutics using its proprietary OPNA platform.
South Korea
244460
A technology platform for therapeutic antibody discovery using transgenic animals.
United States of America
OABIW
ONCIMMUNE HOLDINGS PLC Logo
Immunodiagnostics company specializing in antibody and autoantibody biomarker signatures.
United Kingdom
ONC
Oncocross Co.,Ltd. Logo
An AI biotechnology firm that develops drugs by predicting drug-disease interactions.
South Korea
382150
ONCODESIGN Logo
Develops therapeutic and diagnostic solutions for resistant and metastatic cancers.
France
ALONC

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.